HANDOK INC.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tenelia Elderly CGMS Study(TEDDY)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Teneligliptin
Drug: Placebo

First Posted Date: 2018-04-25

Last Posted Date: 2022-06-30

Lead Sponsor: Handok Inc.

Target Recruit Count: 65

Registration Number: NCT03508323

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH

Conditions: PNH

First Posted Date: 2018-03-09

Last Posted Date: 2018-03-09

Lead Sponsor: Handok Inc.

Target Recruit Count: 236

Registration Number: NCT03460301

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

Phase 4

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Linagliptin
Drug: Teneligliptin

First Posted Date: 2017-01-05

Last Posted Date: 2019-02-22

Lead Sponsor: Handok Inc.

Target Recruit Count: 168

Registration Number: NCT03011177

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Teneligliptin-Glimepiride DDI Study

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Teneligliptin+Glimepiride

First Posted Date: 2017-01-04

Last Posted Date: 2018-05-02

Lead Sponsor: Handok Inc.

Target Recruit Count: 26

Registration Number: NCT03009513

HL2351 CAPS Phase II Study

Phase 2

Terminated

Conditions: Cryopyrin-Associated Periodic Syndromes (CAPS)

Interventions: Drug: HL2351

First Posted Date: 2016-08-02

Last Posted Date: 2017-01-04

Lead Sponsor: Handok Inc.

Target Recruit Count: 8

Registration Number: NCT02853084

Locations: 🇰🇷
Handok Inc., Seoul, Korea, Republic of

Tenelia Triple Combination Study

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Teneligliptin

First Posted Date: 2015-10-05

Last Posted Date: 2018-05-02

Lead Sponsor: Handok Inc.

Target Recruit Count: 201

Registration Number: NCT02567994

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)

Phase 4

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Teneligliptin
Drug: Sitagliptin

First Posted Date: 2015-07-31

Last Posted Date: 2015-10-06

Lead Sponsor: Handok Inc.

Target Recruit Count: 40

Registration Number: NCT02512523

Locations: 🇰🇷
HANDOK Inc., Seoul, Korea, Republic of

A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: Kineret(Anakinra)
Biological: HL2351

First Posted Date: 2014-06-26

Last Posted Date: 2015-10-06

Lead Sponsor: Handok Inc.

Target Recruit Count: 58

Registration Number: NCT02175056

Locations: 🇰🇷
HANDOK Inc., Seoul, Korea, Republic of

Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)

Conditions: Hypertension

First Posted Date: 2013-12-31

Last Posted Date: 2016-01-05

Lead Sponsor: Handok Inc.

Target Recruit Count: 240

Registration Number: NCT02024100

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Bundang-gu, Korea, Republic of

Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: MP513
Drug: Placebo

First Posted Date: 2013-03-06

Last Posted Date: 2015-10-06

Lead Sponsor: Handok Inc.

Target Recruit Count: 189

Registration Number: NCT01805830

Locations: 🇰🇷
Handok Pharmaceuticals CO. LTD, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy